Elaine Nguyen1, Craig I Coleman2, Suresh Nair3, Erin R Weeda4. 1. Idaho State University, College of Pharmacy, Meridian, ID, USA. 2. University of Connecticut, Hartford Hospital Evidence-Based Practice Center, Hartford, CT, USA. 3. University of Connecticut, School of Business, Hartford, CT, USA. 4. Medical University of South Carolina, College of Pharmacy, Charleston, SC, USA. Electronic address: weeda@musc.edu.
Abstract
AIMS: In the Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG) trial, empagliflozin reduced cardiovascular and all-cause mortality in type 2 diabetes (T2D) patients at high cardiovascular risk. We sought to estimate the cost-effectiveness of empagliflozin versus standard treatment for the prevention of cardiovascular morbidity and mortality in patients with T2D. METHODS: A Markov model was developed to assess the cost-effectiveness of empagliflozin (versus standard treatment) for the prevention of cardiovascular morbidity and mortality in patients with T2D using a 3-month cycle length and a lifetime horizon. Data sources included the EMPA-REG randomized clinical trial and other published epidemiological studies. Outcomes included treatment costs (in 2016 US$), quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs). Probabilistic sensitivity analysis (PSA) was performed to test the robustness of conclusions. RESULTS: Empagliflozin use resulted in higher total lifetime treatment costs ($371,450 versus $272,966) but yielded greater QALYs (10.712 vs. 9.419) compared to standard treatment. This corresponded to an ICER of $76,167 per QALY gained. PSA suggested empagliflozin would be cost-effective in 96% of 10,000 iterations assuming a willingness-to-pay threshold of $100,000 per QALY gained. CONCLUSION: Empagliflozin may be cost-effective compared to standard treatment in T2D patients at high cardiovascular risk.
AIMS: In the Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG) trial, empagliflozin reduced cardiovascular and all-cause mortality in type 2 diabetes (T2D) patients at high cardiovascular risk. We sought to estimate the cost-effectiveness of empagliflozin versus standard treatment for the prevention of cardiovascular morbidity and mortality in patients with T2D. METHODS: A Markov model was developed to assess the cost-effectiveness of empagliflozin (versus standard treatment) for the prevention of cardiovascular morbidity and mortality in patients with T2D using a 3-month cycle length and a lifetime horizon. Data sources included the EMPA-REG randomized clinical trial and other published epidemiological studies. Outcomes included treatment costs (in 2016 US$), quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs). Probabilistic sensitivity analysis (PSA) was performed to test the robustness of conclusions. RESULTS:Empagliflozin use resulted in higher total lifetime treatment costs ($371,450 versus $272,966) but yielded greater QALYs (10.712 vs. 9.419) compared to standard treatment. This corresponded to an ICER of $76,167 per QALY gained. PSA suggested empagliflozin would be cost-effective in 96% of 10,000 iterations assuming a willingness-to-pay threshold of $100,000 per QALY gained. CONCLUSION:Empagliflozin may be cost-effective compared to standard treatment in T2D patients at high cardiovascular risk.
Authors: Yohji Matsusaka; Xinyu Chen; Paula Arias-Loza; Rudolf A Werner; Naoko Nose; Takanori Sasaki; Steven P Rowe; Martin G Pomper; Constantin Lapa; Takahiro Higuchi Journal: Mol Imaging Date: 2022-06-21 Impact factor: 3.250
Authors: Ken Lee Chin; Richard Ofori-Asenso; Si Si; Thomas R Hird; Dianna J Magliano; Sophia Zoungas; Danny Liew Journal: Sci Rep Date: 2019-03-01 Impact factor: 4.379
Authors: Phil McEwan; Angharad R Morgan; Rebecca Boyce; Klas Bergenheim; Ingrid A M Gause-Nilsson; Deepak L Bhatt; Lawrence A Leiter; Peter A Johansson; Ofri Mosenzon; Avivit Cahn; John P H Wilding Journal: Diabetes Obes Metab Date: 2021-01-25 Impact factor: 6.577